Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence
H. Wildiers(Breast International Group), R. Paridaens(Breast International Group), Patrick Neven(KU Leuven), A. Prové(GZA Ziekenhuizen Campus Sint-Augustinus), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Tomáš Skácel(Charles University), Pierre Squifflet(International Drug Development Institute (Belgium))
Cited by 30
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994